亞盛醫藥-B(06855.HK)耐立克、APG-2575、APG-115的五項研究進展將在美國血液學會年會展示，其中四項獲口頭報吿
格隆匯11月3日丨亞盛醫藥-B(06855.HK)公吿，公司共有3個在研新藥(耐立克、APG-2575、APG-115)的五項臨牀研究入選第64屆美國血液學會(AmericanSociety of Hematology，ASH)年會展示，其中4項獲口頭報吿。其中，公司原創I類新藥耐立克共有三項臨牀進展獲選口頭報吿。這是該品種的臨牀進展連續第五年入選ASH年會口頭報吿，充分體現國際血液學界對其療效和安全性的認可。同時，公司重要品種Bcl-2選擇性抑制劑APG-2575單藥或聯合治療初治、復發或難治(R/R)慢性淋巴細胞白血病╱小淋巴細胞淋巴瘤(CLL/SLL)患者的全球II期臨牀研究初步數據也獲口頭報吿。此為APG-2575聯合布魯頓氏酪氨酸激酶抑制劑(BTKi)acalabrutinib或利妥昔單抗治療R/R CLL/SLL患者的首次數據公佈。
在耐立克入選2022 ASH年會口頭報吿的臨牀進展中，該品種在美國慢性髓細胞白血病(CML)和費城染色體陽性急性淋巴細胞白血病(Ph+ ALL)患者中的有效性和安全性數據為亞盛醫藥首次公佈，且一經公佈即入選口頭報吿。數據顯示，耐立克在難治性CML和Ph+ ALL患者中的有效性和耐受性良好，即使在ponatinib或asciminib耐藥的患者中，亦顯現出很強的療效。這表明耐立克有望成為全球首個能有效克服ponatinib或asciminib耐藥的新一代BCR-ABL抑制劑。
此外，另外兩項入選口頭報吿的研究分別為該品種治療T315I突變耐藥CML患者的關鍵II期註冊臨牀研究的最新數據，和其用於中國CML耐藥患者的5年長期隨訪數據(I期臨牀研究)，進一步驗證安全性和有效性。
APG-2575在此次ASH年會口頭報吿的數據體現了該品種在R/R CLL/SLL患者中強勁的單藥和聯合治療潛力。數據顯示：APG-2575聯合acalabrutinib治療R/RCLL/SLL的客觀緩解率(ORR)達98%；APG-2575聯合利妥昔單抗治療的ORR達87%。此外，單藥治療的研究結果和前期臨牀研究結果相似，再次展現了APG-2575優秀的療效和安全性；而聯合治療的研究，特別是和acalabrutinib的聯合治療的研究結果，顯示了超高的有效率。同時在腫瘤溶解綜合徵(TLS)的發生率和血液學不良事件等方面，聯合治療也保持了與APG-2575單藥治療相當的出色安全性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
